Min­er­va shares jump as J&J hands over $30M, re­vis­es in­som­nia drug pact; Iroko lays off 122

→ Min­er­va Neu­ro­sciences saw its shares $NERV jump on Thurs­day, af­ter it an­nounced re­vised terms to its col­lab­o­ra­tion with J&J on its orex­in 2 re­cep­tor an­tag­o­nist MIN-202. In a deal con­tin­gent on the clos­ing of J&J’s ac­qui­si­tion of Acte­lion, Min­er­va is get­ting back the shares J&J pur­chas­es along with glob­al rights to the drug. Janssen is giv­ing up its rights to roy­al­ties on the drug and is pay­ing a $30 mil­lion up­front and two pay­ments to­tal­ing $40 mil­lion for late-stage mile­stones. And J&J is for­giv­ing what Min­er­va owes it for mid-stage de­vel­op­ment. Min­er­va will now fund Phase III for in­som­nia on its own.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER